The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -17,298 |
| Stock-based compensation | 2,890 |
| Issuance of shares for services | 27 |
| Accretion of debt issuance costs | 589 |
| Gain on settlement of current liabilities | 2,984 |
| Loss on debt extinguishment | -3,164 |
| Change in fair value of warrant liabilities | 775 |
| Impairment loss on other intangible assets | 5,180 |
| Loss on derivative liability | -230 |
| Deferred income tax benefit | -1,088 |
| Unrealized foreign currency exchange losses (gains) | 99 |
| Prepaid expenses and other current assets | -594 |
| Accounts payable and accrued expenses | -998 |
| Net cash used in operating activities | -10,568 |
| Proceeds from issuance of shares, net of issuance costs | 10,725 |
| Proceeds from issuance of warrants | 1,036 |
| Proceeds from issuance of notes payable | 2,099 |
| Repayment of notes payable and convertible notes | 553 |
| Proceeds from employee vesting of restricted shares | 33 |
| Proceeds from pre-funded warrants | 330 |
| Payments on seller-financed purchases | 499 |
| Net cash provided by financing activities | 13,171 |
| Effect of exchange rates on cash | 1 |
| Net change in cash | 2,604 |
| Cash and restricted cash at beginning of period | 2,659 |
| Cash and restricted cash at end of period | 5,263 |
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)